Latest Press Releases
ImmuVia's IMV-M™'s breakthrough results published in Nature's Scientific Reports
April 8th, 2025
Read Full Press Release →ImmuVia presents IMV-M™ data at 2025's io360 in Boston
March 26th, 2025
Read Full Press Release →ImmuVia Announces Appointment of Daniel Von Hoff to Scientific Advisory Board
March 15th, 2025
Read Full Press Release →ImmuVia's CSO Dr. Goldmacher to present at PEGS 2025
March 1st, 2025
Read Full Press Release →ImmuVia to present at IO360 2025
February 15th, 2025
Read Full Press Release →
A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression
Nature 'Scientific Reports' - March, 2025
Read More→A bispecific antibody overcomes limitations of prior strategies to achieve effective and tumor-selective Death Receptor 5 (DR5) clustering
Preprint (in press) - bioRxiv, January 2025
Read More→ImmuVia Selected To Join Texas Medical Center's 2025 Accelerator for Cancer Therapeutics (ACT)
Texas Medical Center Innovation (TMCi) announces its fifth cohort to the 2025 Accelerator for Cancer Therapeutics (ACT), January 2025
Read More→